Fever News and Research RSS Feed - Fever News and Research

Researchers report possible therapy that could help treat patients infected with SUDV

Researchers report possible therapy that could help treat patients infected with SUDV

Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. [More]
Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections. [More]
Another threat lies in the spread of Chikungunya virus, say experts

Another threat lies in the spread of Chikungunya virus, say experts

While media attention has been focused recently on coronavirus cases in the Arabian peninsula and the Ebola outbreak in West Africa, experts note that another threat lies in the spread of Chikungunya fever, an illness that is transmitted by mosquitoes and can cause fever, joint and muscle pain, headaches, and rashes. While it does not often cause death, the symptoms can be severe and disabling, with no treatment available. [More]
Communications about the benefits of vaccination influence parents' intentions to immunize children

Communications about the benefits of vaccination influence parents' intentions to immunize children

How do parents decide whether to vaccinate their child? In a study designed to formally look at the content of parent-targeted communications about the benefits of vaccination for measles, mumps and rubella, Indiana University School of Medicine investigators report that the framing of these messages influences parents' intentions to immunize their children. [More]
Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway. [More]
Transmission risk of Ebola virus disease during air travel remains low: WHO

Transmission risk of Ebola virus disease during air travel remains low: WHO

The World Health Organization today reiterated its position that the risk of transmission of Ebola virus disease during air travel remains low. [More]
Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose. [More]
Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia. [More]
Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe intractable form of childhood epilepsy. [More]
Studies detect integrons that cause resistance to various antibiotics

Studies detect integrons that cause resistance to various antibiotics

In Mexico the sale of antibiotics for human consumption is controlled to prevent misuse, although in the veterinary sector failure in the implementation of the Official Mexican Standard NOM-064-ZOO-2000, "Guidelines for veterinarian products prescription", has prompted common bacteria such as Escherichia coli and Salmonella spp to become resistant to regular drugs such as streptomycin, trimethoprim, ampicillin, gentamicin, and tetracycline as a result of excess drug use. [More]
Plan International outlines strategies to combat Ebola outbreak

Plan International outlines strategies to combat Ebola outbreak

The current Ebola outbreak, the most severe and complex in history, is now making its impact felt worldwide. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Researchers plan to develop vaccine into a type of antibody serum therapy

Researchers plan to develop vaccine into a type of antibody serum therapy

By many estimates, an Ebola vaccine could be available in humans as early as next year. But will it be the right one? There are a number of vaccines in development and each is in a race to prove that it is most effective, safe and that it will protect the largest number of people. [More]

Treating Americans with untested Ebola drug raises concerns

Using the experimental drug before it is tested in clinical trials will make it difficult to determine whether it is actually safe and effective, say scientists. Meanwhile, African officials say they have been inundated with requests from dying patients and their relatives for the same treatment. [More]
First Edition: August 6, 2014

First Edition: August 6, 2014

Today's headlines include reports about the Gallup-Healthways Well-Being Index that details how politics play a role in the nation's health care gap between red and blue states. [More]
Herpes zoster vaccine effective in protecting older adults against shingles, even after chemotherapy

Herpes zoster vaccine effective in protecting older adults against shingles, even after chemotherapy

The herpes zoster vaccine continues to be effective in protecting older adults against shingles, even after they undergo chemotherapy, according to a Kaiser Permanente study published today in the journal Clinical Infectious Diseases. [More]
NSAID use may mask early pneumonia symptoms

NSAID use may mask early pneumonia symptoms

People with pneumococcal pneumonia who are taking nonsteroidal anti-inflammatory drugs at the point of diagnosis tend to develop more severe disease despite being younger and healthier than those not using these drugs, shows research. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]
Researchers one step closer to finding treatment for dengue fever

Researchers one step closer to finding treatment for dengue fever

There have been several news reports that the world's first dengue vaccine will be available next year. However, the latest clinical trials show that the vaccine only provides a protection of around 50 per cent for DENV-2 and DENV-1, which are commonly found in Singapore. [More]

Researchers discover new vaccine targets to combat malaria

Researchers have discovered new vaccine targets that could help in the battle against malaria. Taking a new, large-scale approach to this search, researchers tested a library of proteins from the Plasmodium falciparum parasite with antibodies produced by the immune systems of a group of infected children. [More]